Abstract: A high-coercivity neodymium-cerium-iron-boron permanent magnet has at least one of the following features: the area of grain boundary RE-rich phases in the magnet accounts for 4% or more of the area of a whole field of view; the grain boundary RE-rich phases in the magnet are fine and uniformly distributed; and the mean value of ratios of the area of block-shaped grain boundary RE-rich phases located at intersections of three or more main-phase grains to the total area of all the three or more adjacent main-phase grains in the vicinity is less than or equal to 30%. RE-rich phases in the magnet are continuously distributed along grain boundaries, thereby increasing the depth of diffusion of a diffusion source into the magnet, improve the uniformity of distribution of the diffusion source in the, and thus further improving the magnetic performance of the diffusion magnet.

Abstract: The present invention provides an in-vitro method for the generation of a population of genetically modified natural killer (NK) cells comprising the steps in the following order: a) obtaining a sample comprising NK cells and other cells, b) enrichment of NK cells from said sample, c) introducing a genetic modifier 1 into said NK cells by electroporation, d) introducing a genetic modifier 2 into said NK cells by transduction, e) expanding said genetically modified NK cells, thereby generating a population of genetically modified NK cells.

Abstract: The present invention pertains to methods and compounds useful in a therapy involving the administration of immune cells to a patient. The method of the invention involves the modification of cells of the immune system with agonists or antagonists of immune regulators such as Interleukin-10 (IL-10) or IL-6, in order to enhance and improve the immunological potential of the immune cells for therapy. Cells modified according to the method of the invention can be administered to a patient to support a treatment of proliferative diseases such as cancer or autoimmune disorders.

Abstract: The invention pertains to bispecific antibodies having two antigen binding specificities, one binding to an epitope of NKG2-D type II integral membrane protein (NKG2D) and one binding to an antigen associated with a disease, preferably a tumor associated- or tumor specific antigen, such as ErbB2 (HER2), CD19, CD20, GD2, PD-L1, EGFR, or EGFRvIII. The bispecific molecules of the invention are preferably applied in the context of the treatment of tumor diseases or infectious diseases. Surprisingly it was found that the use of NKG2D binding specificities that bind in a competitive manner to the NKG2D receptor with its natural ligands such as MICA reduces or prevents the inhibitory effect of ligand shedding. Another advantage of the present invention lies in a synergistic combination of the bispecific molecules of the invention and chimeric antigen receptor (CAR) based therapy.

Abstract: A mesoscale data-based automatic wind turbine layout method and device. The method comprises: initially screening an input wind field region on the basis of input mesoscale wind map data by means of a wind speed limit value to obtain a first wind field region; re-screening the first wind field region on the basis of input terrain data by means of a slope limit value to obtain a second wind field region; and determining, by means of tabu search in which a target wind turbine count and the second wind field region are used as inputs, a wind turbine layout that optimizes an objective function, wherein the objective function is the sum of the annual energy production for wind turbine locations.

Abstract: The present invention pertains to methods and compounds useful in a therapy involving the administration of immune cells to a patient. The method of the invention involves the modification of cells of the immune system with agonists or antagonists of immune regulators such as Interleukin-10 (IL-10) or IL-6, in order to enhance and improve the immunological potential of the immune cells for therapy. Cells modified according to the method of the invention can be administered to a patient to support a treatment of proliferative diseases such as cancer or autoimmune disorders.

Abstract: An organic light-emitting diode (OLED) display panel and an OLED display device are provided. The OLED display panel, by providing an auxiliary water-oxygen barrier layer between the light-emitting functional layer and the substrate, water-oxygen can be isolated by the auxiliary water-oxygen barrier layer even through the gap between the second flexible layer and the second flexible layer and the second barrier layer, thus preventing erosion of the light-emitting functional layer and improving the water-oxygen isolation capacity of the OLED display panels. The technical problem that current active-matrix organic light-emitting diode (AMOLED) display panels, having a poor ability to isolate water-oxygen, is solved.

Abstract: A mesoscale data-based automatic wind turbine layout method and device. The method comprises: initially screening an input wind field region on the basis of input mesoscale wind map data by means of a wind speed limit value to obtain a first wind field region (S100); re-screening the first wind field region on the basis of input terrain data by means of a slope limit value to obtain a second wind field region (S200); and determining, by means of taboo search in which a target wind turbine count and the second wind field region are used as inputs, a wind turbine layout that optimizes an objective function (S300), wherein the objective function is the sum of the annual energy production for wind turbine locations.

Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.

Abstract: A method for locating an object using cluster-type magnetic field is disclosed. The method implemented on an electronic apparatus, comprises: obtaining a wireless signal and a magnetic field signal; performing a first locating for an object according to the wireless signal; and performing a second locating for the object according to the magnetic field signal in the range of the first locating. In addition, an apparatus and a system for locating an object using cluster-type magnetic field are also disclosed. Accordingly, the present invention performs a first rough locating for an object by a wireless signal and then a precise locating for the object in the range of the first locating, thus reducing the amount of calculation, lowering computational complexity and improving accuracy of locating.

Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErhB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying au ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.

Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.

Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.

Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.

Abstract: A method for real-time object locating and mapping includes: 1) performing real-time locating for a moving object in the range of movement; 2) updating a geomagnetic field map in the range of movement of the object in real time according to the locating of the moving object; 3) locating the next position of the moving object according to the updated geomagnetic field map; and repeating steps 2) and 3) until the object stops moving. A device for real-time object locating and mapping is also disclosed. The present application can solve the problem of real-time object locating and accurate geomagnetic field mapping without an indoor priori magnetic field map.